home / stock / repl / repl articles
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercializ...
WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the dev...
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the deve...
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Daktronics posted quarterly ...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow t...
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemipli...
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the dev...
News, Short Squeeze, Breakout and More Instantly...
Replimune Group Inc. Company Name:
REPL Stock Symbol:
NASDAQ Market:
2024-04-24 04:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-14 06:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial eva...